How COMP360 works: 5-HT2A agonism, neuroplasticity, and the DMN

COMP360 psilocybin exerts its antidepressant effects primarily through agonism of the 5-HT2A serotonin receptor, triggering a cascade of downstream changes that distinguish it mechanistically from conventional antidepressants. Unlike selective serotonin reuptake inhibitors, which require chronic dosing to achieve clinical benefit, psilocybin’s therapeutic effects appear to persist long after a single administration — a property that has made it particularly attractive for treatment-resistant depression (TRD), where standard pharmacotherapy has failed at least twice.

The mechanism unfolds across four interlocking pathways. First, 5-HT2A receptor agonism in cortical pyramidal neurons modulates monoaminergic neurotransmitter systems and triggers changes in glutamatergic transmission. Second, psilocybin acts as a psychoplastogen — promoting long-lasting neuroplasticity through dendritic spine growth and upregulation of brain-derived neurotrophic factor (BDNF) in hippocampal and prefrontal regions. Third, it produces acute disruption of the default mode network (DMN), the resting-state brain network associated with rumination and self-referential thought that is typically hyperconnected in depression. Fourth, anti-inflammatory effects and the psychological experience itself — often described as a shift in self-perception and emotional processing — are proposed as additional contributors.

Functional neuroimaging studies have confirmed that acute DMN disruption and increases in thalamocortical connectivity correlate with lasting remission in TRD patients. These biomarkers are now being explored as predictors of treatment outcome in ancillary studies attached to Phase III programmes — a move that could eventually support patient stratification and precision prescribing. According to research published in Nature Neuroscience, increases in brain entropy and global functional connectivity following psilocybin administration are among the most consistently observed neuroimaging signatures.

What the COMP005 Phase 2b data actually showed

The COMP005 trial (NCT04670081) is the pivotal Phase 2b dataset underpinning COMP360’s advance to Phase III, and its results established a clear dose-response relationship that has shaped the entire development programme. The study was a 12-week, double-blind, randomised, dose-finding trial conducted in 233 participants with TRD across 22 sites in Europe and North America — the largest controlled psilocybin trial in TRD at the time of reporting.

The dose-dependent response across all three arms — 1 mg, 10 mg, and 25 mg — was the key regulatory signal. The 1 mg arm functioned as an active control rather than a true placebo, a design choice that addresses one of the sector’s most persistent methodological criticisms: the impossibility of blinding participants to a full psychedelic dose. The overall safety profile of COMP360 was reported as acceptable across all dose groups.

“At 3 weeks, COMP360 25 mg resulted in a reduction from baseline on the MADRS of -12.0 points — a dose-dependent response that supports the 25 mg dose for further investigation in Phase III.”

Secondary analysis of the COMP005 data has also begun to identify predictors of treatment response, including baseline MADRS scores, prior treatment history, and patient characteristics that may moderate outcome. These findings are informing patient selection strategies for the Phase III programme — a critical step toward demonstrating that COMP360 can deliver consistent benefit in a broader, more heterogeneous population than a tightly controlled Phase 2b trial.

Compass Pathways’ IP estate and the COMP360 formulation moat

Compass Pathways has built a layered intellectual property position around COMP360 that extends well beyond the compound itself. COMP360 is the only psilocybin hydrochloride (psilocybin HCl) salt form in clinical development, and this distinction is backed by a portfolio of patents covering the crystalline polymorph, the synthesis process, and the clinical administration method.

The foundational patent, US11851451B2, claims novel synthetic processes for producing high-purity crystalline psilocybin (polymorph A), characterised by specific X-ray powder diffraction patterns. This crystalline form claim is significant because it creates a barrier to generic competition even after the compound itself enters the public domain — a strategy analogous to the polymorph protection used in small-molecule pharmaceuticals more broadly. Methods of treating depression, TRD, and anxiety using this crystalline formulation are also claimed within the same patent.

A subsequent application, US20230057659A1, covers methods of treating psychiatric disorders including TRD using psilocybin in combination with psychological support and specific dosing regimens — extending IP coverage from the molecule into the therapy protocol itself. A further application, US20240139189A1, expands coverage to formulations of psilocybin in stable salt forms and specific session protocols, with dose ranges of between 1 mg and 30 mg of psilocybin HCl.

This approach — protecting the salt form, the polymorph, the method of use, and the administration protocol as separate IP layers — reflects a broader trend in psychedelic drug development where the compound itself may be difficult to patent exclusively, but the clinical delivery system offers durable protection. According to WIPO data, patent filings in the psychedelic therapeutics space have grown substantially since 2019, with formulation and method-of-use claims accounting for an increasing share of new applications.

MindMed MM-120 vs. COMP360: the psychedelic readout race

Compass Pathways is furthest advanced in psilocybin for TRD, but MindMed’s MM-120 programme represents the most direct competitive pressure in the psychedelic-assisted therapy space. MM-120 is a tartrate salt form of LSD (lysergic acid diethylamide) — a full agonist at serotonin 5-HT2A and 5-HT2B receptors, with additional activity at dopaminergic and adrenergic receptors that distinguishes its pharmacological profile from psilocybin.

MM-120’s Phase 2b data in generalised anxiety disorder (GAD) showed statistically significant reductions in HAM-A scores versus placebo at 12-week follow-up. MindMed has announced a Phase 3 programme called MAIA for MM-120 in GAD, positioning it as a competitor to Compass Pathways in the broader psychedelic medicine space even though the two companies are targeting different primary indications — TRD for Compass Pathways, GAD for MindMed — with different molecules.

The competitive dynamics extend beyond the two companies. MAPS/Lykos Therapeutics had been advancing MDMA-assisted therapy for PTSD as the sector’s most advanced programme, but the FDA’s rejection of that application in 2024 materially changed the landscape. Key competitive variables for Compass Pathways and MindMed now include Phase 3 readout timing, regulatory strategy including Breakthrough Therapy Designations, and the scalability of the therapy model — particularly the requirement for trained psychological support personnel during sessions, which creates cost and access constraints that regulators and payers will scrutinise. As noted in research published by NIH-indexed journals, the requirement for psychological support in psychedelic-assisted therapy sessions is simultaneously a therapeutic asset and a commercial bottleneck.

Phase III design challenges: blinding, SSRIs, and the post-MDMA regulatory climate

Blinding integrity is the most fundamental methodological challenge in designing Phase III trials for psilocybin, and it is one the field has not yet fully resolved. Participants in active treatment groups are readily unblinded due to the pronounced subjective effects of psychedelic compounds, potentially inflating placebo-controlled effect sizes through expectancy and therapeutic alliance effects. This is not a theoretical concern — it has been identified by the FDA as an active scientific review question for COMP360’s Phase III programme.

Strategies under discussion include active placebo design using low-dose psychedelics, niacin controls, and rater blinding — where the clinicians assessing MADRS outcomes are kept unaware of treatment assignment. Robust blinding verification methodologies are recommended as co-primary or secondary endpoints in pivotal trials. The COMP005 Phase 2b design partially addressed this by using 1 mg as an active control rather than an inert placebo, but the adequacy of this approach for a Phase III submission remains a regulatory question.

The SSRI co-medication question is particularly consequential for Phase III design. The COMP005 Phase 2b trial allowed for SSRI washout, but the Phase III design reportedly examines co-administration scenarios — a pragmatic choice that would increase the real-world applicability of results but introduces pharmacodynamic complexity. Preclinical data suggest that chronic SSRI use may reduce 5-HT2A receptor density, potentially attenuating psilocybin’s effects, yet clinical data from small studies indicate that psilocybin retains meaningful antidepressant efficacy even in the presence of SSRI co-medication.

The regulatory environment has been further complicated by the FDA’s 2024 rejection of Lykos Therapeutics’ MDMA-assisted therapy application. That decision — the first time an FDA advisory committee had reviewed a psychedelic-assisted therapy for approval — created uncertainty across the sector regarding the evidentiary standards required for approval. The FDA’s expectations for psychedelic-assisted therapies remain a critical uncertainty for Phase III trial design for all companies in the space. Compass Pathways holds Breakthrough Therapy Designation for COMP360 in TRD, which provides a formal channel for FDA engagement on trial design questions, but does not guarantee a clear regulatory pathway. According to guidance published by the FDA, Breakthrough Therapy Designation is intended to expedite development and review but does not lower the evidentiary bar for approval.

For drug developers and IP professionals tracking this space, the primary endpoint — the Montgomery-Åsberg Depression Rating Scale (MADRS) — is established as the regulatory standard for TRD trials, and durability of effect beyond the 3-week primary endpoint timepoint used in COMP005 will need to be demonstrated. Evidence of durability up to 3–6 months has been reported in some psilocybin studies, according to systematic reviews published in Nature-indexed journals, but Phase III will need to establish this more rigorously in a larger, more diverse population. The PatSnap drug discovery intelligence platform provides real-time tracking of trial registrations, protocol amendments, and patent filings across the psychedelic therapy pipeline — enabling teams to monitor COMP360’s Phase III progress and competitive developments as they happen.